SemBioSys to present new data at American Diabetes Association annual meeting

    TSX symbol: SBS

    CALGARY, June 20 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), a
biotechnology company developing a portfolio of therapeutic proteins for
metabolic and cardiovascular disease, today announced that it will be
presenting a scientific poster and abstract at the 67th Scientific Sessions of
the American Diabetes Association (ADA) in Chicago. The Company's poster will
disclose recent accomplishments in the development of a highly-scalable, low
cost source of recombinant human insulin. Poster session presentations will
take place at the McCormick Place Convention Center on Saturday June 23 from
6:00pm to 7:15 pm and on Monday June 25 from 12:00pm to 2:00pm. The poster and
abstract are titled:
    "Chemical and Biological Characterization of Recombinant Human Insulin
Produced in Transgenic Plants." Abstract Number 0459-P by Joseph Boothe, Cory
Nykiforuk, Elizabeth Murray, Philip Kuhlman, W. Brent Pollock, Amanda Bodero,
Joseph Goren, Richard Keon, Nancy Markley, and Maurice Moloney.

    About SemBioSys Genetics Inc. (

    Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company
developing insulin and other protein-based pharmaceuticals for metabolic and
cardiovascular diseases. The Company's lead candidate is recombinant human
insulin produced in the plant host safflower, to serve the rapidly expanding
global diabetes market and to supply insulin for inhalation and other
alternative insulin delivery technologies. The Company's other protein-based
pharmaceutical candidate is a cardiovascular drug called Apo AI. SemBioSys is
also developing a series of non-pharmaceutical products addressing animal and
aquaculture health, nutritional oils and human topical markets.

    This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.

    %SEDAR: 00020947E

For further information:

For further information: SemBioSys Genetics Inc., Mr. Andrew Baum,
President and Chief Executive Officer, Phone: (403) 717-8767, Fax: (403)
250-3886, E-mail:, Internet:; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail:

Organization Profile

SemBioSys Genetics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890